Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xevinapant plus radiotherapy versus placebo plus radiotherapy in resected high-risk head and neck squamous cell carcinoma ineligible for high-dose cisplatin
NL-OMON56150Phase 3Recruiting
- Sponsor
- Merck KGaA
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in head and neck squamous cell carcinoma (HNSCC) comparing Xevinapant arm with Placebo arm (2 arms). Primary endpoint: Disease-Free Survival. Started Mar 2024; status: recruiting.
02
Drugs
xevinapant
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NL-OMON56150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56150.